
Boston Scientific’s January acquisitions of Valencia and Penumbra caught my attention. There is a clear strategic thread: the real value is the IP and procedural know-how that can plug into BSX’s existing platforms and scale fast. Sharing my take:
linkedin.com/pulse/strategi…
English











